E.Y. de Brabander

De Brabander, E. Y., Breddels, E., van Amelsvoort, T., van Westrhenen, R., & Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2024). Clinical effects of CYP2D6 phenoconversion in patients with psychosis. Journal of Psychopharmacology, 38(12), 1095-1110. https://doi.org/10.1177/02698811241278844

De Brabander, E. Y., van Amelsvoort, T., van Westrhenen, R., & Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2024). Unidentified CYP2D6 genotype does not affect pharmacological treatment for patients with first episode psychosis. Journal of Psychopharmacology, 38(12), 1111-1121. https://doi.org/10.1177/02698811241279022

de Brabander, E., Kleine Schaars, K., van Amelsvoort, T., Budde, M., Heilbronner, U., Young, A. H., Juruena, M., Vieta, E., Fares-Otero, N. E., Kas, M. J., Nöthen, M., Philipsen, A., Kilarski, L. L., Laatsch, J., Rossner, M. J., Wichert, S. P., Moldovan, R., Shomron, N., Schulze, T. G., ... PSY-PGx Consortium (2024). Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review. Journal of Psychiatric Research, 174, 137-152. https://doi.org/10.1016/j.jpsychires.2024.04.001